Monthly
US$200
Billed every month
Neostigmine Methylsulfate Injection(甲硫酸新斯的明注射液)
Companies, stages and changes, with each record available on this page.
Last 90 days: Accepted: 2 applications
Current coverage may be incomplete
Which companies are listed, and at what stages?
Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.
Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.
Catalogue holders20View records ↓
Under-review filings4View records ↓
This year’s generic filers2View records ↓
NHSA approval numbers41View records ↓
API companies with A status12View records ↓
Chemical-drug catalogue
Loaded records: 20 holders; 3 in the quality-and-efficacy consistency-evaluation category, and 17 in the new chemical-registration-classification generic category. Category counts may overlap.
| Marketing authorization holder | Manufacturer | Approval number | Approved | Strength / specification | Catalogue category (source text) | View source |
|---|---|---|---|---|---|---|
| 南京海辰药业股份有限公司 | 南京海辰药业股份有限公司 | 国药准字H20255920 | 2025/11/12 | 1ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京海辰药业股份有限公司 | 南京海辰药业股份有限公司 | 国药准字H20255921 | 2025/11/12 | 2ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 南京海辰药业股份有限公司 | 南京海辰药业股份有限公司 | 国药准字H20255919 | 2025/11/12 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州市联瑞制药有限公司 | 广州市联瑞制药有限公司 | 国药准字H20255676 | 2025/10/14 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河北一品制药股份有限公司 | 河北一品制药股份有限公司 | 国药准字H20255575 | 2025/09/23 | 2ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南埃威格林医药科技有限公司 | 湖南华纳大药厂股份有限公司 | 国药准字H20255251 | 2025/08/26 | 1ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 湖南埃威格林医药科技有限公司 | 湖南华纳大药厂股份有限公司 | 国药准字H20255250 | 2025/08/26 | 2ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宝利化（南京）制药有限公司 | 江苏华阳制药有限公司 | 国药准字H20254190 | 2025/05/20 | 2ml：1mg | Not stated by source | CDE |
| 杭州民生药业股份有限公司 | 杭州民生药业股份有限公司 | 国药准字H20254160 | 2025/05/13 | 1ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州民生药业股份有限公司 | 杭州民生药业股份有限公司 | 国药准字H20254161 | 2025/05/13 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州民生药业股份有限公司 | 杭州民生药业股份有限公司 | 国药准字H20254162 | 2025/05/13 | 2ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南先施药业有限公司 | 四川科伦药业股份有限公司 | 国药准字H20254142 | 2025/05/13 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 云南先施药业有限公司 | 四川科伦药业股份有限公司 | 国药准字H20254141 | 2025/05/13 | 1ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 宝利化（南京）制药有限公司 | 江苏华阳制药有限公司 | 国药准字H20254179 | 2025/05/13 | 1ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海旭东海普药业有限公司 | 上海旭东海普药业有限公司 | 国药准字H20253701 | 2025/03/25 | 2ml：1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海旭东海普药业有限公司 | 上海旭东海普药业有限公司 | 国药准字H20253700 | 2025/03/25 | 1ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州瑞尔医药科技有限公司 | 河北凯威制药有限责任公司 | 国药准字H20258016 | 2025/02/18 | 2ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 东阳祥昇医药科技有限公司 | 浙江北生药业汉生制药有限公司 | 国药准字H20249616 | 2024/12/01 | 1ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 东阳祥昇医药科技有限公司 | 浙江北生药业汉生制药有限公司 | 国药准字H20249617 | 2024/12/01 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥亿帆生物制药有限公司 | 合肥亿帆生物制药有限公司 | 国药准字H20249340 | 2024/11/15 | 2ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥亿帆生物制药有限公司 | 合肥亿帆生物制药有限公司 | 国药准字H20249339 | 2024/11/15 | 1ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 山西振东泰盛制药有限公司 | 山西振东泰盛制药有限公司 | 国药准字H20249320 | 2024/11/15 | 2ml∶1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 合肥亿帆生物制药有限公司 | 合肥亿帆生物制药有限公司 | 国药准字H20249341 | 2024/11/15 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 浙江仙琚制药股份有限公司 | 浙江仙琚制药股份有限公司 | 国药准字H20247239 | 2024/10/11 | 4ml:2mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 浙江仙琚制药股份有限公司 | 浙江仙琚制药股份有限公司 | 国药准字H20057097 | 2024/10/11 | 1ml:0.5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 江苏九旭药业有限公司 | 江苏九旭药业有限公司 | 国药准字H20244656 | 2024/08/13 | 1ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 江苏九旭药业有限公司 | 江苏九旭药业有限公司 | 国药准字H20244657 | 2024/08/13 | 4ml：2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 陕西丽彩药业有限公司 | 山西诺成制药有限公司 | 国药准字H20244008 | 2024/06/11 | 1ml:0.5mg | Not stated by source | CDE |
| 陕西丽彩药业有限公司 | 山西诺成制药有限公司 | 国药准字H20244009 | 2024/06/11 | 2ml:1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州瑞尔医药科技有限公司 | 河北凯威制药有限责任公司 | 国药准字H20243425 | 2024/04/07 | 1ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 广州瑞尔医药科技有限公司 | 河北凯威制药有限责任公司 | 国药准字H20243426 | 2024/04/07 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 杭州沐源生物医药科技有限公司 | 成都市海通药业有限公司 | 国药准字H20243285 | 2024/02/23 | 1ml：0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 河南润弘制药股份有限公司 | 河南润弘制药股份有限公司 | 国药准字H20237110 | 2023/09/11 | 2ml：1mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 河南润弘制药股份有限公司 | 河南润弘制药股份有限公司 | 国药准字H41022269 | 2023/09/11 | 1ml：0.5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 成都苑东生物制药股份有限公司 | 成都苑东生物制药股份有限公司 | 国药准字H20233878 | 2023/06/30 | 4ml:2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都苑东生物制药股份有限公司 | 成都苑东生物制药股份有限公司 | 国药准字H20233879 | 2023/06/30 | 1ml:0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海信谊金朱药业有限公司 | 上海信谊金朱药业有限公司 | 国药准字H31021570 | 2023/01/09 | 1ml:0.5mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
| 成都欣捷高新技术开发股份有限公司 | 太极集团四川太极制药有限公司 | 国药准字H20223715 | 2022/09/30 | 1ml∶0.5mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都欣捷高新技术开发股份有限公司 | 太极集团四川太极制药有限公司 | 国药准字H20223716 | 2022/09/30 | 4ml∶2mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 成都欣捷高新技术开发股份有限公司 | 太极集团四川太极制药有限公司 | 国药准字H20223714 | 2022/09/30 | 2ml∶1mg | Generic approved under the new chemical-drug registration classification (按化学药品新注册分类批准的仿制药) | CDE |
| 上海信谊金朱药业有限公司 | 上海信谊金朱药业有限公司 | 国药准字H31022770 | 2022/03/09 | 2ml:1mg | Drug that passed quality-and-efficacy consistency evaluation (通过质量和疗效一致性评价的药品) | CDE |
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
NHSA drug codes
Loaded records: 41 distinct approval numbers and 20 companies.
| Company / applicant | Approval number | Strength / specification | NHSA class | NHSA drug code | View source |
|---|---|---|---|---|---|
| 上海信谊金朱药业有限公司 | 国药准字H31022770 | 2ml:1mg | Category A (甲) | XN07AAX155B002010100801 | NHSA |
| 上海旭东海普药业有限公司 | 国药准字H20253701 | 2ml:1mg | Category A (甲) | XN07AAX155B002010100816 | NHSA |
| 江苏浦金药业有限公司 | 国药准字H20044811 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010101424 | NHSA |
| 南京海辰药业股份有限公司 | 国药准字H20255919 | 4ml:2mg | Category A (甲) | XN07AAX155B002010101563 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20233878 | 4ml:2mg | Category A (甲) | XN07AAX155B002010102181 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20223715 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010102305 | NHSA |
| 河北一品制药股份有限公司 | 国药准字H20255575 | 2ml:1mg | Category A (甲) | XN07AAX155B002010102632 | NHSA |
| 河南润弘制药股份有限公司 | 国药准字H41022269 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010103257 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20254160 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010104494 | NHSA |
| 浙江仙琚制药股份有限公司 | 国药准字H20057097 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010104735 | NHSA |
| 江苏九旭药业有限公司 | 国药准字H20244656 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010110146 | NHSA |
| 山西振东泰盛制药有限公司 | 国药准字H20249320 | 2ml∶1mg | Category A (甲) | XN07AAX155B002010179230 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20249339 | Iml:0.5mg | Category A (甲) | XN07AAX155B002010182719 | NHSA |
| 广州市联瑞制药有限公司 | 国药准字H20255676 | 4ml:2mg | Category A (甲) | XN07AAX155B002010183238 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20243425 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010183450 | NHSA |
| 陕西丽彩药业有限公司 | 国药准字H20244008 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010183540 | NHSA |
| 云南先施药业有限公司 | 国药准字H20254141 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010183585 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20243285 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010184135 | NHSA |
| 东阳祥昇医药科技有限公司 | 国药准字H20249616 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010184294 | NHSA |
| 湖南埃威格林医药科技有限公司 | 国药准字H20255251 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010184441 | NHSA |
| 上海信谊金朱药业有限公司 | 国药准字H31022770 | 2ml:1mg | Category A (甲) | XN07AAX155B002010200801 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20233878 | 4ml:2mg | Category A (甲) | XN07AAX155B002010202181 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20223715 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010202305 | NHSA |
| 河北一品制药股份有限公司 | 国药准字H20255575 | 2ml:1mg | Category A (甲) | XN07AAX155B002010202632 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20254160 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010204494 | NHSA |
| 浙江仙琚制药股份有限公司 | 国药准字H20057097 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010204735 | NHSA |
| 江苏九旭药业有限公司 | 国药准字H20244656 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010210146 | NHSA |
| 山西振东泰盛制药有限公司 | 国药准字H20249320 | 2ml∶1mg | Category A (甲) | XN07AAX155B002010279230 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20243425 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010283450 | NHSA |
| 陕西丽彩药业有限公司 | 国药准字H20244008 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010283540 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20243285 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010284135 | NHSA |
| 东阳祥昇医药科技有限公司 | 国药准字H20249616 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010284294 | NHSA |
| 上海信谊金朱药业有限公司 | 国药准字H31022770 | 2ml:1mg | Category A (甲) | XN07AAX155B002010300801 | NHSA |
| 杭州沐源生物医药科技股份有限公司 | 国药准字H20243285 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002010384135 | NHSA |
| 上海旭东海普药业有限公司 | 国药准字H20253700 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002020100816 | NHSA |
| 江苏浦金药业有限公司 | 国药准字H20044812 | 2ml:1mg | Category A (甲) | XN07AAX155B002020101424 | NHSA |
| 南京海辰药业股份有限公司 | 国药准字H20255920 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002020101563 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20233879 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002020102181 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20223714 | 2ml:1mg | Category A (甲) | XN07AAX155B002020102305 | NHSA |
| 河南润弘制药股份有限公司 | 国药准字H41022269 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002020103257 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20254161 | 4ml:2mg | Category A (甲) | XN07AAX155B002020104494 | NHSA |
| 浙江仙琚制药股份有限公司 | 国药准字H20247239 | 4ml:2mg | Category A (甲) | XN07AAX155B002020104735 | NHSA |
| 江苏九旭药业有限公司 | 国药准字H20244657 | 4ml:2mg | Category A (甲) | XN07AAX155B002020110146 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20249340 | 2ml:1mg | Category A (甲) | XN07AAX155B002020182719 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20243426 | 4ml:2mg | Category A (甲) | XN07AAX155B002020183450 | NHSA |
| 陕西丽彩药业有限公司 | 国药准字H20244009 | 2ml:1mg | Category A (甲) | XN07AAX155B002020183540 | NHSA |
| 云南先施药业有限公司 | 国药准字H20254142 | 4ml:2mg | Category A (甲) | XN07AAX155B002020183585 | NHSA |
| 东阳祥昇医药科技有限公司 | 国药准字H20249617 | 4ml:2mg | Category A (甲) | XN07AAX155B002020184294 | NHSA |
| 湖南埃威格林医药科技有限公司 | 国药准字H20255250 | 2ml:1mg | Category A (甲) | XN07AAX155B002020184441 | NHSA |
| 上海信谊金朱药业有限公司 | 国药准字H31021570 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002020200801 | NHSA |
| 成都苑东生物制药股份有限公司 | 国药准字H20233879 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002020202181 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20223714 | 2ml:1mg | Category A (甲) | XN07AAX155B002020202305 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20254161 | 4ml:2mg | Category A (甲) | XN07AAX155B002020204494 | NHSA |
| 江苏九旭药业有限公司 | 国药准字H20244657 | 4ml:2mg | Category A (甲) | XN07AAX155B002020210146 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20243426 | 4ml:2mg | Category A (甲) | XN07AAX155B002020283450 | NHSA |
| 陕西丽彩药业有限公司 | 国药准字H20244009 | 2ml:1mg | Category A (甲) | XN07AAX155B002020283540 | NHSA |
| 东阳祥昇医药科技有限公司 | 国药准字H20249617 | 4ml:2mg | Category A (甲) | XN07AAX155B002020284294 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20243426 | 4ml:2mg | Category A (甲) | XN07AAX155B002020383450 | NHSA |
| 上海信谊金朱药业有限公司 | 国药准字H31021570 | 1ml:0.5mg | Category A (甲) | XN07AAX155B002030100801 | NHSA |
| 南京海辰药业股份有限公司 | 国药准字H20255921 | 2ml:1mg | Category A (甲) | XN07AAX155B002030101563 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20223716 | 4ml:2mg | Category A (甲) | XN07AAX155B002030102305 | NHSA |
| 河南润弘制药股份有限公司 | 国药准字H20237110 | 2ml:1mg | Category A (甲) | XN07AAX155B002030103257 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20254162 | 2ml:1mg | Category A (甲) | XN07AAX155B002030104494 | NHSA |
| 合肥亿帆生物制药有限公司 | 国药准字H20249341 | 4ml:2mg | Category A (甲) | XN07AAX155B002030182719 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20258016 | 2ml:1mg | Category A (甲) | XN07AAX155B002030183450 | NHSA |
| 成都欣捷高新技术开发股份有限公司 | 国药准字H20223716 | 4ml:2mg | Category A (甲) | XN07AAX155B002030202305 | NHSA |
| 河南润弘制药股份有限公司 | 国药准字H20237110 | 2ml:1mg | Category A (甲) | XN07AAX155B002030203257 | NHSA |
| 杭州民生药业股份有限公司 | 国药准字H20254162 | 2ml:1mg | Category A (甲) | XN07AAX155B002030204494 | NHSA |
| 广州瑞尔医药科技有限公司 | 国药准字H20258016 | 2ml:1mg | Category A (甲) | XN07AAX155B002030283450 | NHSA |
Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.
Current under-review applications
Loaded records: 4 filings and 2 distinct first applicants.
Generic 4
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏福邦药业有限公司 | CYHS2600503 | Generic | 2026/02/25 | Not stated by source | CDE |
| 江苏福邦药业有限公司 | CYHS2600502 | Generic | 2026/02/25 | Not stated by source | CDE |
| 河南合智医药科技有限公司;酒泉大得利制药股份有限公司 | CYHS2602346 | Generic | 2026/09/20 | Not stated by source | CDE |
| 河南合智医药科技有限公司;酒泉大得利制药股份有限公司 | CYHS2602345 | Generic | 2026/09/20 | Not stated by source | CDE |
New generic filings in 2026
Loaded records: 4 filings and 2 distinct first applicants.
| Company / applicant | Acceptance number | Application type | Accepted | Strength / specification | View source |
|---|---|---|---|---|---|
| 江苏福邦药业有限公司 | CYHS2600503 | Generic | 2026/02/25 | Not stated by source | CDE |
| 江苏福邦药业有限公司 | CYHS2600502 | Generic | 2026/02/25 | Not stated by source | CDE |
| 河南合智医药科技有限公司;酒泉大得利制药股份有限公司 | CYHS2602346 | Generic | 2026/09/20 | Not stated by source | CDE |
| 河南合智医药科技有限公司;酒泉大得利制药股份有限公司 | CYHS2602345 | Generic | 2026/09/20 | Not stated by source | CDE |
API registrations
Non-component matches: 12 companies with A status and 6 I-status records. Component matches are listed separately and excluded from these counts.
| Name | Company / applicant | Registration number | Status | Name match | Source update date | View source |
|---|---|---|---|---|---|---|
| 甲硫酸新斯的明 | 浙江北生药业汉生制药有限公司 | Y20260000775 | I | Exact ingredient | 2026/09/17 | CDE |
| 甲硫酸新斯的明 | 湖南华纳大药厂手性药物有限公司 | Y20260000613 | I | Exact ingredient | 2026/08/21 | CDE |
| 甲硫酸新斯的明 | 河南精康制药有限公司 | Y20260000285 | I | Exact ingredient | 2026/05/19 | CDE |
| 甲硫酸新斯的明 | 西安力邦制药有限公司 | Y20260000003 | I | Exact ingredient | 2026/02/02 | CDE |
| 甲硫酸新斯的明 | 云鹏医药集团有限公司 | Y20250001209 | I | Exact ingredient | 2025/11/25 | CDE |
| 甲硫酸新斯的明 | 成都百裕制药股份有限公司 | Y20240000332 | A | Exact ingredient | 2026/05/02 | CDE |
| 甲硫酸新斯的明 | 南京海辰药业股份有限公司 | Y20230001155 | A | Exact ingredient | 2025/11/19 | CDE |
| 甲硫酸新斯的明 | 浙江赛默制药有限公司 | Y20230000615 | A | Exact ingredient | 2025/03/19 | CDE |
| 甲硫酸新斯的明 | 上海旭东海普药业有限公司 | Y20230000442 | A | Exact ingredient | 2024/12/13 | CDE |
| 甲硫酸新斯的明 | 江苏华泰晨光药业有限公司 | Y20220000755 | A | Exact ingredient | 2025/03/01 | CDE |
| 甲硫酸新斯的明 | 浙江海昇药业股份有限公司 | Y20220000042 | A | Exact ingredient | 2025/05/24 | CDE |
| 甲硫酸新斯的明 | 江苏九旭药业有限公司 | Y20220000073 | A | Exact ingredient | 2026/05/20 | CDE |
| 甲硫酸新斯的明 | 四川青木制药有限公司 | Y20210001123 | A | Exact ingredient | 2025/02/27 | CDE |
| 甲硫酸新斯的明 | MSN Laboratories Private Limited | Y20200001426 | A | Exact ingredient | 2024/01/31 | CDE |
| 甲硫酸新斯的明 | 成都新恒创药业有限公司 | Y20210000033 | A | Exact ingredient | 2024/01/17 | CDE |
| 甲硫酸新斯的明 | 浙江仙琚制药股份有限公司 | Y20190007552 | A | Exact ingredient | 2024/01/25 | CDE |
| 甲硫酸新斯的明 | 上海中西三维药业有限公司 | Y20190002743 | A | Exact ingredient | 2025/03/05 | CDE |
| 甲硫酸新斯的明 | 江西制药有限责任公司 | Y20170000189 | I | Exact ingredient | — | CDE |
A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.
What changed recently?
Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.
Trial registration does not mean an application will follow.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.
-
2026/09/20Accepted
河南合智医药科技有限公司;酒泉大得利制药股份有限公司
CYHS2602346
Fact date: 2026/09/20 · Site observation date: 2026/10/22
View source ↗ -
2026/09/20Accepted
河南合智医药科技有限公司;酒泉大得利制药股份有限公司
CYHS2602345
Fact date: 2026/09/20 · Site observation date: 2026/10/22
View source ↗
How current is each source?
- CDE acceptances and review
- Last successful update: 2026/11/10 07:27
- Chemical-drug catalogue
- Last successful update: 2026/11/10 07:23
Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.
- Full API register
- Last successful update: 2026/11/10 07:25
- NHSA drug codes
- Last successful update: 2026/11/05 06:45
The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.
- NMPA drug delivery notices
- Last successful update: 2026/11/10 18:31
First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.
- Drug Clinical Trial Registry and Information Disclosure Platform
- Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete
Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.
This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.
Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.
Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.
Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.
Free follow
Follow changes to Neostigmine Methylsulfate Injection
Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.
Subscriptions
Next-day facts and deliverable timelines
- One email the next day when new facts are collected for your followed products.
- Export the complete loaded event timeline for each followed product as CSV.
- Add up to 4 additional recipients, each confirmed by email.
- Increase your follow limit from 3 to 10 products.
Quarterly
US$540
Billed every three months
US$180 per month
Yearly
US$1,920
Billed every year
US$160 per month
Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.
Separate one-time purchase
US Orange Book × China records comparison
Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.
Subscriptions and comparison-table access are purchased separately. Neither includes the other.
US$490
One payment · 12 months of access
Online comparison-table purchase is not enabled.
Billed by Creem, our merchant of record · Terms · Refund policy